The company currently holds 1.68
M in liabilities with Debt to Equity (D/E) ratio of 0.15, which may suggest Biomerica is not taking enough advantage from borrowing. Biomerica has a current ratio of 6.25, suggesting that it is liquid enough and is able to pay its financial obligations when due.
The firm shows a Beta (market volatility) of 0.0602, which signifies not very significant fluctuations relative to the market. Let's try to break down what Biomerica's beta means in this case. As returns on the market increase, Biomerica returns are expected to increase less than the market. However, during the bear market, the loss on holding Biomerica will be expected to be smaller as well. Even though it is essential to pay attention to
Biomerica historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's
future performance is to check both, its past performance charts as well as the business as a whole, including all available
technical indicators. Biomerica exposes twenty-eight different technical indicators, which can help you to evaluate its performance.
Biomerica has an expected return of -0.31%. Please be advised to confirm Biomerica
downside variance,
daily balance of power, and the
relationship between the
maximum drawdown and
skewness to decide if
Biomerica stock performance from the past will be repeated at some point in the near future.
We determine the current worth of Biomerica using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Biomerica based exclusively on its
fundamental and basic
technical indicators. By analyzing Biomerica's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of
Biomerica's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biomerica. We calculate exposure to Biomerica's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Biomerica's related companies.
Watch out for price decline
Please consider monitoring Biomerica on a daily basis if you are holding a position in it. Biomerica is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Biomerica stock to be traded above the $1 level to remain listed. If Biomerica stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Biomerica Investment Alerts
Biomerica investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Biomerica performance across your portfolios.Please check all
investment alerts for Biomerica
Biomerica Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Biomerica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biomerica competition to find
correlations between indicators driving the intrinsic value of Biomerica.
Biomerica Gross Profit
Biomerica Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Biomerica previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Biomerica Gross Profit growth over the last 10 years. Please check Biomerica's
gross profit and other
fundamental indicators for more details.
A Deeper Perspective
The entity reported the previous year's revenue of 6.42
M. Net Loss for the year was (4.48
M) with profit before overhead, payroll, taxes, and interest of 1.78
M.
Margins Breakdown
Biomerica profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Biomerica itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Biomerica profit margins.
| EBITDA Margin | (0.27) |
| Gross Margin | 0.26 |
| Profit Margin | (0.32) |
Biomerica Earnings before Tax is somewhat stable at the moment. Further, Biomerica Average Assets is somewhat stable at the moment.
Is Biomerica growth trustworthy after the slip?
The jensen alpha is down to 0.12 as of today. Biomerica shows above-average downside volatility for the selected time horizon. We advise investors to inspect Biomerica further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Biomerica future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biomerica's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biomerica's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Whereas other companies in the diagnostics & research industry are either recovering or due for a correction, Biomerica may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 13th of April 2021, we see that Biomerica barely shadows the market. The company is
undervalued with
very low odds of financial turmoil within the next 24 months. However, our latest 30 days buy-hold-sell recommendation on the company is
Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Biomerica. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com